*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated November 16, 2026 (the "**Prospectus**") issued by Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (北京先通國際醫藥科技股份有限公司) (the "**Company**").*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the "**Stabilizing Manager**"), or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting for it) to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager (or any person acting for it) and may be discontinued at any time.*

Any such stabilizing action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, November 24, 2026).

Beijing Sinotau International Pharmaceutical Technology Co., Ltd.
北京先通國際醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	**:**	**6,561,000 H Shares (subject to the Over-allotment Option)**
Number of Hong Kong Offer Shares	**:**	**656,100 H Shares**
Number of International Offer Shares	**:**	**5,904,900 H Shares (subject to the Over-allotment Option)**
Final Offer Price	**:**	**HK$52.0 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and AFRC transaction levy of 0.00015%, and Hong Kong Stock Exchange trading fee of 0.00565%**
Nominal Value	**:**	**RMB1.00 per H Share**
Stock Code	**:**	**9941**

Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

广发证券 GF SECURITIES (Independent Sponsor) CICC 中金公司 CITIC SECURITIES

(in no particular order)

Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

招銀国际 CMB INTERNATIONAL

Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

DBS 星展集团 中國銀河國際 CHINA GALAXY INTERNATIONAL

Joint Bookrunners and Joint Lead Managers

中銀國際 BOCI ABCI 農銀國際 國聯證券國際 交銀國際 BOCOM International

民銀資本 浙商國際 富途證券 老虎證券

Beijing Sinotau International Pharmaceutical Technology Co., Ltd.
北京先通國際醫藥科技股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus issued by the Company.

Warning: In view of high concentration of shareholding in a small number of H Shareholders, so Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock code	9941
Stock short name	SINOTAUPHARMA-B
Dealings commencement date	November 24, 2026*

* *see note at the end of the announcement*

Price Information	
Offer Price	HK$52.0

Offer Shares and Share Capital	
Number of Offer Shares (before exercise of Over-allotment Option)	6,561,000 H Shares
Final Number of Offer Shares in Hong Kong Public Offering	656,100 H Shares
Final Number of Offer Shares in International Offering (before exercise of Over-allotment Option)	5,904,900 H Shares
Number of issued shares upon Listing (before exercise of Over-allotment Option)	65,609,614 Shares

Over-allocation	
Number of Offer Shares over-allocated	328,050

Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.

Proceeds	
Gross proceeds[(Note)]	HK$341.2 million
Less: Estimated listing expenses payable based on Offer Price	HK$64.6 million
Net proceeds	HK$276.6 million

Note: Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" of the Prospectus. Any discrepancies in the table between the aggregate amount and the sums of individual amounts listed therein are due to rounding. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus on a pro rata basis.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	129,458
No. of successful applications	13,122
Subscription level	5,228.77 times
Reallocation	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	656,100
No. of Offer Shares reallocated from the International Offering	N/A
Final no. of Offer Shares under the Hong Kong Public Offering	656,100
% of Offer Shares under the Hong Kong Public Offering to the Global Offering (before exercise of Over-allotment Option)	10%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	61
Subscription Level	3.01 times
No. of Offer Shares initially available under the International Offering	5,904,900
Final no. of Offer Shares under the International Offering (before exercise of Over-allotment Option)	5,904,900
% of Offer Shares under the International Offering to the Global Offering (before exercise of Over-allotment Option)	90%

*The Directors confirm that, to the best of their knowledge, information and belief, save for consents under paragraphs 1C(2) of Appendix F1 to the Listing Rules (the "**Placing Guidelines**") granted by the Stock Exchange to permit the Company to, among other things, place certain H Shares in the International Offering to certain close associates of existing Shareholders, (i) none of the Offer Shares subscribed by the placees and the public offer subscribers have been financed directly or indirectly by the Company, any of the Directors, chief executives, supervisors of the Company, Single Largest Shareholders Group, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; (ii) none of the placees and the public offer subscribers who have subscribed for or purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executives, supervisors of the Company, Single Largest Shareholders Group, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it; (iii) there is no side agreement or arrangement between the Company, any of the Directors, chief executives, supervisors of the Company, Single Largest Shareholders Group, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates, on one hand, and the public offer subscribers or the placees who have subscribed for or purchased the Offer Shares, on the other hand; (iv) there is no side agreement or arrangement between the Company, any of the Directors, chief executives, supervisors of the Company, Single Largest Shareholders Group, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close*

associates, on one hand, and any other parties, on the other hand, in connection with the subscription, purchase, disposal, turnover or valuation of the Shares (which, for the avoidance of doubt, does not include agreement entered into with the pricing stabilizing managers); and (v) no rebate has been, directly or indirectly, provided by the Company, any of the Directors, chief executive, supervisors of the Company, Single Largest Shareholders Group, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates, or syndicate members, or any other brokers involved in the Global Offering, to any investors in the Hong Kong Public Offering or placees in the International Offering.

The placees in the International Offering include the following:

Allottees with Consents Obtained

Investor	*No. of Offer Shares allocated*	*% of Offer Shares (assuming the Over-allotment Option is not exercised)*	*% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)*	*Relationship*
Allottees with consents under paragraph 1C(1) of Appendix F1 to the Listing Rules (the "Placing Guidelines") in relation to allocations to connected clients[Note 1]				
GF Securities Asset Management (Guangdong) Co., Ltd. ("**GF Securities AM**")	376,700	5.74%	0.57%	Connected client as a placee
China Asset Management (Hong Kong) Limited ("**China AMC HK**")	500	0.01%	0.001%	Connected client as a placee
Bosera Asset Management (International) Co., Ltd ("**Bosera International**")	500	0.01%	0.001%	Connected client as a placee
Orient Securities Asset Management Company Limited (上海東方證券資產管理有限公司) ("**Orient AM**")	113,000	1.72%	0.17%	Connected client as a placee

Investor	*No. of Offer Shares allocated*	*% of Offer Shares (assuming the Over-allotment Option is not exercised)*	*% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)*	*Relationship*
Allottees with consent under paragraph 1C(2) of the Placing Guidelines in relation to allocations to close associates of existing Shareholders				
China AMC HK[Note 2]	500	0.01%	0.001%	A close associate of existing Shareholders
GF Securities AM[Note 3]	376,700	5.74%	0.57%	A close associate of an existing Shareholder

Note:

1. *For details of the consents under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed "Others/Additional Information – Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines" in this announcement.*

2. *As of the Latest Practicable Date, GoldStone New Material Fund for Manufacturing Transformation and Upgrading (Limited Partnership) ("**GoldStone New Material Fund**"), Maotai GoldStone (Guizhou) Bio-technology Industry Fund Limited Partnership (Limited Partnership) ("**Maotai GoldStone Fund**") and CITIC Securities Investment Co., Ltd. ("**CITIC Securities**", together with GoldStone New Material Fund and Maotai GoldStone Fund, the "**CITIC Existing Shareholders**") are existing Shareholders which held approximately 7.71%, 1.21% and 0.96% of the total issued Shares, respectively. CITIC GoldStone Investment Co., Ltd., a wholly-owned subsidiary of CITIC Securities Company Limited ("**CITIC Securities Company**"), is the general partner of GoldStone New Material Fund and one of the general partners of Maotai GoldStone Fund, and CITIC Securities is a wholly-owned subsidiary of CITIC Securities Company. Under the SFO, CITIC Securities Company is deemed to be interested in the Shares held by the CITIC Existing Shareholders, being an aggregate of 5,839,403 Shares, representing approximately 9.89% of the total issued Shares as of the Latest Practicable Date. China AMC HK is wholly owned by China Asset Management Co., Ltd., which is in turn owned as to approximately 62.2% by CITIC Securities Company. China AMC HK is therefore a fellow subsidiary, and hence a close associate, of CITIC Securities, an existing Shareholder. China AMC HK will hold the Offer Shares allocated to it in its capacity as the discretionary fund manager of ChinaAMC China Growth Fund (SICAV) on behalf of its investors, each of which is an independent third party, and no proprietary money of China AMC HK or any member of its group will be used for the subscription. Immediately following completion of the Global Offering and before the exercise of the Over-allotment Option, the CITIC Existing Shareholders and China AMC HK are expected to collectively hold approximately 8.90% of the total issued Shares. For details of the consent under paragraph 1C(2) of the Placing Guidelines, please refer to the section headed "Others/Additional Information – Placing to close associates of existing Shareholders as placees with prior consent under paragraph 1C(2) of the Placing Guidelines" in this announcement.*

3. *As of the Latest Practicable Date, GF Qianhe Investment Co., Ltd. (廣發乾和投資有限公司) ("**GF Qianhe**"), a wholly-owned subsidiary of GF Securities, held 498,770 Shares, representing approximately 0.84% of the total issued Shares. Each of GF Qianhe and GF Securities AM is a direct wholly-owned subsidiary of GF Securities. GF Securities AM is therefore a fellow subsidiary, and hence a close associate, of GF Qianhe, an existing Shareholder. GF Securities AM will hold the Offer Shares allocated to it in its capacity as the discretionary manager of the GF Securities AM Plans on behalf of the GF Securities AM Plan Investors, each of which is an independent third party, and no proprietary money of GF Securities AM or any member of its group will be used for the subscription. Immediately following completion of the Global Offering and before the exercise of the Over-allotment Option, GF Qianhe and GF Securities AM are expected to collectively hold approximately 1.33% of the total issued Shares. For details of the consent under paragraph 1C(2) of the Placing Guidelines, please refer to the section headed "Others/Additional Information – Placing to close associates of existing Shareholders as placees with prior consent under paragraph 1C(2) of the Placing Guidelines" in this announcement.*

LOCK-UP UNDERTAKINGS

Single Largest Shareholders Group

Name[Note 1]	*Number of Shares held in the Company subject to lock-up undertakings immediately upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
Mr. Xu	6,686,142	10.19%	November 23, 2027
Xue Fei	1,453,183	2.21%	November 23, 2027
Chu Wei	1,157,318	1.76%	November 23, 2027
Liu Shuang	868,378	1.32%	November 23, 2027
Ms. Tang	740,032	1.13%	November 23, 2027
Qi Hui	268,700	0.41%	November 23, 2027
Wang Peng	188,316	0.29%	November 23, 2027
Beijing Sinotau Juxin	1,775,726	2.71%	November 23, 2027
Beijing Sinotau Juli	864,054	1.32%	November 23, 2027
Tianjin Sinotau Juzhi	799,557	1.22%	November 23, 2027
Tianjin Sinotau Juneng	799,556	1.22%	November 23, 2027
Beijing Sinotau Juhui	361,711	0.55%	November 23, 2027
Total	**15,962,673**	**24.33%**	

Note:

1. *For details of the Single Largest Shareholders Group, please refer to the "Substantial Shareholders" section of the Prospectus.*

2. *The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.*

Pre-IPO Investors (as defined in the "History, Development and Corporate Structure" section of the Prospectus)

Name[Note 1]	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
Zhang Yingjie	936,934	1.43%	November 23, 2027
Wuming Futian	1,133,459	1.73%	November 23, 2027
Mingde Weixin No. 9	964,114	1.47%	November 23, 2027
Wuming Boji	725,634	1.11%	November 23, 2027
Mingde Weixin No. 1	262,268	0.40%	November 23, 2027
Mingde Weixin No. 7	230,470	0.35%	November 23, 2027
Jiaxing Weixin	205,235	0.31%	November 23, 2027
Jiequan Chengda	5,918,762	9.02%	November 23, 2027
GoldStone New Material Fund[Note 2]	4,552,894	6.94%	November 23, 2027
Maotai GoldStone Fund[Note 3]	717,397	1.09%	November 23, 2027
CICC Qide	2,328,804	3.55%	November 23, 2027
Pharmaceutical Fund	2,276,447	3.47%	November 23, 2027
Hetang Innovation	1,605,144	2.45%	November 23, 2027
Chongqing Hetang	363,876	0.55%	November 23, 2027
Tongfu Fund	1,889,100	2.88%	November 23, 2027
China Structural Reform Fund II	1,707,335	2.60%	November 23, 2027

Name[Note 1]	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
Nanjing Zhengkai	1,598,749	2.44%	November 23, 2027
Qiming Rongxin	1,151,442	1.75%	November 23, 2027
Qiming Rongchuang	270,092	0.41%	November 23, 2027
Guotou Guangdong	1,138,223	1.73%	November 23, 2027
Genertec VC Company	1,138,223	1.73%	November 23, 2027
Guoyao Zhongsheng	1,124,463	1.71%	November 23, 2027
Shengcheng Investment	8,996	0.01%	November 23, 2027
Wuxi Guolian	569,112	0.87%	November 23, 2027
Wuxi Shanghang	432,416	0.66%	November 23, 2027
Tianjin Panya	784,920	1.20%	November 23, 2027
Jiaxing Yaotong	420,594	0.64%	November 23, 2027
Jiaxing Yaojin	310,280	0.47%	November 23, 2027
Deyi Xinhua	575,030	0.88%	November 23, 2027
CITIC Securities[Note 3]	569,112	0.87%	November 23, 2027
Guoke Dingzhi	566,730	0.86%	November 23, 2027
Jilin Xinsheng	512,201	0.78%	November 23, 2027
GF Qianhe	498,770	0.76%	November 23, 2027
Li Jianxin	484,048	0.74%	November 23, 2027
Longshen No. 6	465,761	0.71%	November 23, 2027
Zhuxi Healthcare	341,467	0.52%	November 23, 2027
Zhongshan Talent	227,645	0.35%	November 23, 2027
Qingshi Zhenhe	318,703	0.49%	November 23, 2027

Name[Note 1]	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
Cheng Haowen	287,190	0.44%	November 23, 2027
Zhizheng VC	273,174	0.42%	November 23, 2027
Liu Rui	241,505	0.37%	November 23, 2027
Langma No. 36	232,880	0.35%	November 23, 2027
Nanjing Enjie VC	227,645	0.35%	November 23, 2027
Zhongshan Jintou	227,645	0.35%	November 23, 2027
Rural Industry Fund	227,645	0.35%	November 23, 2027
Wanlong Investment	226,237	0.34%	November 23, 2027
Jiangsu Wangao	188,910	0.29%	November 23, 2027
Zou Xianghong	169,477	0.26%	November 23, 2027
Mu Tianzhi	169,477	0.26%	November 23, 2027
Yuanhui Ruize	155,254	0.24%	November 23, 2027
Mao Ruijuan	147,445	0.22%	November 23, 2027
Zhang Di'ou	135,582	0.21%	November 23, 2027
Boyu Zhiyuan	117,920	0.18%	November 23, 2027
Boyu Kuntong	114,619	0.17%	November 23, 2027
Boyu Kexing	108,928	0.17%	November 23, 2027
Zhuhai Chunxiao	113,822	0.17%	November 23, 2027
Yizhuang Investment	103,502	0.16%	November 23, 2027
LI Yinqiang (李銀強)	94,193	0.14%	November 23, 2027
LI Guangyao (李光耀)	23,899	0.04%	November 23, 2027
YANG Xuejuan (楊雪娟)	22,961	0.03%	November 23, 2027

Name[Note 1]	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
YANG Ke (楊克)	14,009	0.02%	November 23, 2027
LIAO Jidong (廖繼東)	11,949	0.02%	November 23, 2027
YAO Yizhu (姚奕竹)	11,907	0.02%	November 23, 2027
Tongzi Zhongzhi	11,382	0.02%	November 23, 2027
WAN Xiaojun (萬小軍)	11,303	0.02%	November 23, 2027
Jinyi Hongda	10,472	0.02%	November 23, 2027
DONG Xiantao (董顯濤)	9,420	0.01%	November 23, 2027
YAO Yabiao (姚亞彪)	9,419	0.01%	November 23, 2027
CHEN Yanfeng (陳艷鋒)	9,419	0.01%	November 23, 2027
ZHANG Xusheng (張旭升)	7,170	0.01%	November 23, 2027
ZHAO Lihong (趙麗虹)	4,780	0.01%	November 23, 2027
ZHANG Jinqian (張近前)	4,710	0.01%	November 23, 2027
MA Donghua (馬冬花)	3,768	0.01%	November 23, 2027
GUO Zhiying (郭志穎)	3,768	0.01%	November 23, 2027
LI Changju (李昌菊)	3,585	0.01%	November 23, 2027
LIU Yiqun (劉一群)	3,585	0.01%	November 23, 2027
LI Heng (李恒)	2,826	0.004%	November 23, 2027
LV Yingying (呂英英)	2,826	0.004%	November 23, 2027
HAO Jin (郝晉)	2,390	0.004%	November 23, 2027
ZHANG Zhixin (張志新)	1,884	0.003%	November 23, 2027
LI Xiangping (李湘平)	1,195	0.002%	November 23, 2027
LIU Xuehu (劉學虎)	1,195	0.002%	November 23, 2027

Name[Note 1]	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 2]
PENG Sha (彭莎)	1,195	0.002%	November 23, 2027
CAO Fengqi (曹峰琦)	1,179	0.002%	November 23, 2027
YANG Lifeng (楊麗鳳)	1,093	0.002%	November 23, 2027
ZHAO Rongrong (趙融融)	984	0.001%	November 23, 2027
ZHANG Xiaoju (張曉菊)	942	0.001%	November 23, 2027
ZHANG Ying (張英)	942	0.001%	November 23, 2027
LIU Yue (劉躍)	942	0.001%	November 23, 2027
LUAN Tian (欒天)	942	0.001%	November 23, 2027
Total	**43,085,941**	**65.67%**	

Note:

1. *For details of the Pre-IPO Investors, please refer to the section headed "History, Development and Corporate Structure" of the Prospectus.*

2. *The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.*

3. *The numbers of Shares held by the CITIC Existing Shareholders and GF Qianhe in the table above do not take into account the Offer Shares allocated to China AMC HK, a close associate of the CITIC Existing Shareholders, and GF Securities AM, a close associate of GF Qianhe, respectively, in the International Offering. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to China AMC HK and GF Securities AM. For details, please refer to the sections headed "Allottees with Consents Obtained" and "Others/Additional Information – Placing to close associates of existing Shareholders as placees with prior consent under paragraph 1C(2) of the Placing Guidelines" in this announcement.*

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares Allotted	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is not exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is exercised)	Number of Shares Held Upon Listing	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is not exercised)	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is exercised)
Top 1	1,500,000	25.40%	24.07%	22.86%	21.77%	1,500,000	2.29%	2.27%
Top 5	3,646,900	61.76%	58.51%	55.58%	52.94%	3,646,900	5.56%	5.53%
Top 10	5,068,600	85.84%	81.32%	77.25%	73.57%	5,567,370	8.49%	8.44%
Top 25	6,056,950	102.57%	97.18%	92.32%	87.92%	6,555,720	9.99%	9.94%

Note

* *Ranking of placees is based on the number of H Shares allotted to the placees.*

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares Allotted	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is not exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is exercised)	Number of H Shares Held Upon Listing	H Shares Held Upon Listing as % of Total Issued H Share Capital Upon Listing (assuming the Over-allotment Option is not exercised)	H Shares Held Upon Listing as % of Total Issued H Share Capital Upon Listing (assuming the Over-allotment Option is exercised)	Number of Shares Held Upon Listing	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is not exercised)	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is exercised)
Top 1	0	0.00%	0.00%	0.00%	0.00%	7,981,339	19.45%	19.30%	15,962,673	24.33%	24.21%
Top 5	500	0.01%	0.01%	0.01%	0.01%	19,432,753	47.37%	46.99%	36,113,400	55.04%	54.77%
Top 10	1,500,500	25.41%	24.07%	22.87%	21.78%	26,321,611	64.16%	63.65%	45,085,031	68.72%	68.38%
Top 25	4,024,100	68.15%	64.56%	61.33%	58.41%	34,901,448	85.07%	84.39%	55,381,787	84.41%	83.99%

Note

* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares Allotted	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is not exercised)	Allotment as % of Total Offer Shares (assuming the Over-allotment Option is exercised)	Number of H Shares Held Upon Listing	H Shares Held Upon Listing as % of Total Issued H Share Capital Upon Listing (assuming the Over-allotment Option is not exercised)	H Shares Held Upon Listing as % of Total Issued H Share Capital Upon Listing (assuming the Over-allotment Option is exercised)	Number of Shares Held Upon Listing	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is not exercised)	Shares Held Upon Listing as % of Total Issued Share Capital Upon Listing (assuming the Over-allotment Option is exercised)
Top 1	0	0.00%	0.00%	0.00%	0.00%	7,981,339	19.45%	19.30%	15,962,673	24.33%	24.21%
Top 5	500	0.01%	0.01%	0.01%	0.01%	19,432,753	47.37%	46.99%	36,113,400	55.04%	54.77%
Top 10	1,500,500	25.41%	24.07%	22.87%	21.78%	26,321,611	64.16%	63.65%	45,085,031	68.72%	68.38%
Top 25	3,214,700	54.44%	51.58%	49.00%	46.66%	33,588,902	81.87%	81.22%	57,364,355	87.43%	87.00%

Note

* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT POOL A	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
50	14,768	222 out of 14,768 to receive 50 Shares	1.50%
100	20,708	401 out of 20,708 to receive 50 Shares	0.97%
150	5,373	121 out of 5,373 to receive 50 Shares	0.75%
200	3,138	78 out of 3,138 to receive 50 Shares	0.62%
250	3,269	89 out of 3,269 to receive 50 Shares	0.54%
300	2,542	74 out of 2,542 to receive 50 Shares	0.49%
350	1,558	48 out of 1,558 to receive 50 Shares	0.44%
400	1,708	55 out of 1,708 to receive 50 Shares	0.40%
450	1,321	45 out of 1,321 to receive 50 Shares	0.38%
500	3,257	114 out of 3,257 to receive 50 Shares	0.35%
600	3,142	118 out of 3,142 to receive 50 Shares	0.31%
700	5,508	218 out of 5,508 to receive 50 Shares	0.28%
800	1,407	59 out of 1,407 to receive 50 Shares	0.26%
900	1,006	44 out of 1,006 to receive 50 Shares	0.24%
1,000	6,104	276 out of 6,104 to receive 50 Shares	0.23%
1,500	3,499	184 out of 3,499 to receive 50 Shares	0.18%
2,000	1,661	97 out of 1,661 to receive 50 Shares	0.15%
2,500	1,667	106 out of 1,667 to receive 50 Shares	0.13%
3,000	1,283	87 out of 1,283 to receive 50 Shares	0.11%
3,500	907	65 out of 907 to receive 50 Shares	0.10%
4,000	938	71 out of 938 to receive 50 Shares	0.09%
4,500	780	61 out of 780 to receive 50 Shares	0.09%
5,000	1,438	118 out of 1,438 to receive 50 Shares	0.08%
6,000	1,180	103 out of 1,180 to receive 50 Shares	0.07%
7,000	1,199	111 out of 1,199 to receive 50 Shares	0.07%
8,000	1,041	101 out of 1,041 to receive 50 Shares	0.06%
9,000	846	86 out of 846 to receive 50 Shares	0.06%
10,000	5,878	621 out of 5,878 to receive 50 Shares	0.05%
20,000	3,643	525 out of 3,643 to receive 50 Shares	0.04%

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
		POOL A	
30,000	2,861	453 out of 2,861 to receive 50 Shares	0.03%
40,000	2,094	375 out of 2,094 to receive 50 Shares	0.02%
50,000	1,882	376 out of 1,882 to receive 50 Shares	0.02%
60,000	1,760	357 out of 1,760 to receive 50 Shares	0.02%
70,000	3,458	702 out of 3,458 to receive 50 Shares	0.01%
	112,824	**Total number of Pool A successful applicants: 6,561**	
		POOL B	
80,000	3,960	950 out of 3,960 to receive 50 Shares	0.01%
90,000	1,978	527 out of 1,978 to receive 50 Shares	0.01%
100,000	2,595	753 out of 2,595 to receive 50 Shares	0.01%
125,000	1,511	521 out of 1,511 to receive 50 Shares	0.01%
150,000	1,217	486 out of 1,217 to receive 50 Shares	0.01%
175,000	712	319 out of 712 to receive 50 Shares	0.01%
200,000	655	328 out of 655 to receive 50 Shares	0.01%
225,000	402	219 out of 402 to receive 50 Shares	0.01%
250,000	389	231 out of 389 to receive 50 Shares	0.01%
275,000	297	191 out of 297 to receive 50 Shares	0.01%
300,000	326	216 out of 326 to receive 50 Shares	0.01%
328,050	2,592	1,820 out of 2,592 to receive 50 Shares	0.01%
	16,634	**Total number of Pool B successful applicants: 6,561**	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules in respect of which consents have been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, consents under paragraph 1C(1) of the Placing Guidelines to permit certain Offer Shares to be placed to connected clients of connected distributors under the International Offering pursuant to the Placing Guidelines. Details of the placement to connected clients are set out below. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consents granted by the Stock Exchange. Please also refer to the section headed "Allottees with Consents Obtained" in this announcement for details.

Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties

No.	Connected Distributor	Connected Client	Relationship with the Connected Distributor	Whether the Connected Client is a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme	Maximum number of Offer Shares (rounded down to nearest whole board lot of 50 Shares) to be allocated to the connected client	Approximate percentage of total number of Offer Shares (assuming the Over-allotment Option is not exercised)	Approximate percentage of total Shares in issue immediately following the completion of Global Offering (assuming the Over-allotment Option is not exercised)
1.	CLSA Limited ("**CLSA**")	China AMC HK	See Note 1	No	500	0.01%	0.001%
2.	CMB International Securities Limited ("**CMBI**")	Bosera International	See Note 2	No	500	0.01%	0.001%
3.	Orient Securities (Hong Kong) Limited ("**Orient Securities**")	Orient AM	See Note 3	Yes	113,000	1.72%	0.17%
4.	GF Securities (Hong Kong) Brokerage Limited ("**GF Securities (Hong Kong) Brokerage**")	GF Securities AM	See Note 4	No	376,700	5.74%	0.57%

Notes:

1. China AMC HK

China AMC HK is a member of the same group of companies as CLSA as each of China AMC HK and CLSA is a subsidiary of CITIC Securities Company, and is therefore considered as a connected client of CLSA pursuant to paragraph 1B(7) of the Placing Guidelines.

China AMC HK will hold the Offer Shares in its capacity as the discretionary fund manager managing the fund on behalf of its investors, each of which is, to the best knowledge of China AMC HK after due enquiry, an independent third party of the Company, its subsidiaries, its substantial shareholders, China AMC HK, CLSA and the companies which are members of the same group of companies as CLSA, and no proprietary money of China AMC HK or any member of its group will be used for the subscription.

The fund is as follows:

(a) CHINAAMC CHINA GROWTH FUND (SICAV), of which the investor holding 30% or more interest is Yuanta Securities (HK) Company Limited, holding approximately 73.17% interest, whose ultimate beneficial owner is Yuanta Financial Holding Co., Ltd., a company listed on the Taiwan Stock Exchange (stock code: 2885).

2. Bosera International

CMBI is a distributor of the Global Offering. Bosera International is held as to 55% by Bosera Asset Management Co., Ltd. and 45% by China Merchants Fund Management Co., Ltd. China Merchants Bank Co., Ltd. currently holds 55% of the equity interest of China Merchants Fund Management Co., Ltd. CMBI is an indirect wholly-owned subsidiary of China Merchants Bank Co., Ltd. Therefore, Bosera International is a member of the same group of companies as CMBI, and is therefore considered as a connected client of CMBI pursuant to paragraph 1B(7) of the Placing Guidelines.

Bosera International intends to subscribe for and hold the Offer Shares in its capacity as the discretionary fund manager on behalf of its sub-fund. To the best knowledge of Bosera International after due enquiry, the sub-fund, its investor holding 30% or more interest and such investor's ultimate beneficial owner holding 30% or more interest are independent third parties of the Company, its subsidiaries, its substantial shareholders, Bosera International, CMBI and the companies which are members of the same group of companies as CMBI.

Details of the sub-fund are set out below:

Name of the sub-fund	**Investor(s) holding 30% or more interest and its ultimate beneficial owner(s) holding 30% or more interest (if any)**
Bosera Growth Premium Global Equity Strategy Fund SP	Junasset Limited Partnership, whose ultimate beneficial owner holding 30% or more interest is Guo Feng (郭峰)

3. Orient AM

Orient AM is a direct wholly-owned asset management subsidiary of Orient Securities Company Limited (東方證券股份有限公司), and Orient Securities is an indirect wholly-owned subsidiary of Orient Securities Company Limited held through Orient Finance Holdings (Hong Kong) Limited and its wholly-owned subsidiary, Orient Securities International Financial Group Limited. Orient AM is therefore a member of the same group of companies as Orient Securities, and is considered as a connected client of Orient Securities pursuant to paragraph 1B(7) of the Placing Guidelines.

Orient AM will hold the Offer Shares in its capacity as the discretionary fund manager managing DFH Medical Innovation Hybrid Fund (QDII) (東方紅醫療創新混合型證券投資基金(QDII)) (the "**DFH QDII Fund**") on behalf of its investors (the "**DFH QDII Fund Investors**"). No DFH QDII Fund Investor holds 30% or more interest in the DFH QDII Fund. To the best knowledge of Orient AM after due enquiry, the DFH QDII Fund and each of the DFH QDII Fund Investors are independent third parties of the Company, its subsidiaries, its substantial shareholders, Orient AM, Orient Securities and the companies which are members of the same group of companies as Orient Securities, and no proprietary money of Orient AM or any member of its group will be used for the subscription. The ultimate beneficial owner of Orient AM is Orient Securities Company Limited.

The DFH QDII Fund is a collective investment scheme which is not authorised by the SFC. It is a contractual open-ended publicly offered securities investment fund registered with the China Securities Regulatory Commission (Zheng Jian Xu Ke [2025] No. 1546), whose fund contract became effective on September 18, 2025, with Shanghai Pudong Development Bank Co., Ltd. as its domestic custodian and Citibank N.A. as its overseas custodian. Orient AM, a fund management company established in the PRC and approved as a QDII, manages the DFH QDII Fund on a discretionary basis, and the DFH QDII Fund Investors have no right to direct the acquisition or disposal of the Offer Shares.

4. GF Securities AM

GF Securities AM is a direct wholly-owned subsidiary of GF Securities Co., Ltd. (stock code: 1776) ("**GF Securities**"). GF Securities (Hong Kong) Brokerage is an indirect wholly-owned subsidiary of GF Securities. Accordingly, GF Securities AM is a member of the same group of companies as GF Securities (Hong Kong) Brokerage, and is therefore considered as a connected client of GF Securities (Hong Kong) Brokerage pursuant to paragraph 1B(7) of the Placing Guidelines.

GF Securities AM, an asset manager approved by the relevant PRC authority as a qualified domestic institutional investor ("**QDII**"), will subscribe for and hold the Offer Shares as a placee under the International Offering in its capacity as the discretionary manager of the asset management plans disclosed below (the "**GF Securities AM Plans**") on behalf of the investors of the GF Securities AM Plans (the "**GF Securities AM Plan Investors**"). GF Securities AM, in the name of the GF Securities AM Plans, will hold the legal title of the Offer Shares, and the GF Securities AM Plan Investors have no right to direct the acquisition or disposal of the Offer Shares. To the best knowledge of GF Securities AM after due enquiry, each of the GF Securities AM Plans, the GF Securities AM Plan Investors holding 30% or more interest therein and their ultimate beneficial owners holding 30% or more interest are independent third parties of the Company, its subsidiaries, its substantial shareholders, GF Securities AM, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage, and no proprietary money of GF Securities AM or any member of its group will be used for the subscription.

The GF Securities AM Plans are as follows:

(a) CIB-GFAM CHINA HK STOCKS MULTISTRATEGY AMA NO.7 (廣發資管港股多元策略7號單一資產管理計劃(QDII)), of which the investor holding 30% or more interest is Zhonghe Capital Cultivation 920 Private Securities Investment Fund 中和資本耕耘920號私募證券投資基金, whose ultimate beneficial owner is Zhang Jingting (張敬庭).

(b) SPDB – GF SECURITIES ASSET MANAGEMENT (GUANGDONG) CO., LTD. CHKMS AMA NO.12 (廣發資管港股多元策略12號單一資產管理計劃 (QDII)), of which the investor holding 30% or more interest is Zhonghe Capital Cultivation 810 Private Securities Investment Fund 中和資本耕耘810號私募證券投資基金, whose ultimate beneficial owner is Zhang Jingting (張敬庭).

GF Securities AM is not a collective investment scheme which is not authorised by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.

Placing to close associates of existing Shareholders as placees with prior consent under paragraph 1C(2) of the Placing Guidelines

The Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to (i) China AMC HK, a close associate of the CITIC Existing Shareholders; and (ii) GF Securities AM, a close associate of GF Qianhe, on the following grounds which are consistent with the conditions as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide for New Listing Applicants (the "**Guide**"):

(1) the Company will comply with the public float requirement under Rule 19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the Listing Rules;

(2) the CITIC Existing Shareholders, aggregated on a CITIC Securities Company group basis, together held approximately 9.89% of the total issued Shares, and GF Qianhe held approximately 0.84% of the total issued Shares, in each case as of the Latest Practicable Date, being less than 10% of the Shares prior to the Global Offering, and each of China AMC HK and GF Securities AM is therefore permitted to subscribe for Offer Shares as a placee;

(3) no preference in allocation has been, nor will be, given to China AMC HK or GF Securities AM as a placee by virtue of being a close associate of the CITIC Existing Shareholders or GF Qianhe (as applicable) in any allocation in the placing tranche of the Global Offering;

(4) each of the Company, the Joint Sponsors and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide, including that (i) no preferential treatment has been, nor will be, given to China AMC HK or GF Securities AM by virtue of its relationship with the Company, the CITIC Existing Shareholders or GF Qianhe (as applicable) in any allocation in the placing tranche; (ii) neither CLSA nor GF Securities (Hong Kong) Brokerage has participated, or will participate, in the decision-making process or relevant discussions as to whether Offer Shares should be allocated to China AMC HK or GF Securities AM (as applicable); and (iii) the allocations will not affect the Company's ability to satisfy the public float and free float requirements under the Listing Rules; and

(5) the relevant information in respect of the allocations to China AMC HK and GF Securities AM as placees has been disclosed in this allotment results announcement.

Such allocations of Offer Shares are in compliance with all the conditions under the consent granted by the Stock Exchange.

DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*
The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated November 16, 2026 issued by Beijing Sinotau International Pharmaceutical Technology Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.
** Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, November 24, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately after the completion of the Global Offering (before any exercise of the Over-allotment Option), an aggregate of 29,544,445 H Shares, representing 45.03% of the total issued Shares upon the Listing which is higher than the prescribed percentage of H Shares required to be held in public hands of 25% under Rule 19A.13A(1) of the Listing Rules, will be counted towards the public float. Hence, the Company will be able to comply with Rule 19A.13A(1) of the Listing Rules.

Pursuant to the applicable PRC law, within the 12 months following the Listing Date, all existing Shareholders (including the Pre-IPO Investors) cannot dispose of any of the Shares held by them. As such, the H Shares held by the existing Shareholders upon the Listing shall not be counted towards the free float of the H Shares of the Company at the time of Listing. Based on the Offer Price of HK$52.0 per Offer Share, the Company will satisfy the free float requirement under Rule 19A.13C of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering (assuming the Over-allotment Option is not exercised): (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder under the Listing Rules immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Shares are participating securities from the Listing Date and will be issued in Uncertificated Form, and no physical share certificate(s) or other document of title will be issued and dispatched in respect of the H Shares. All of the Offer Shares will be registered on the register of holders of H Shares maintained by the Company's ASR, Computershare Hong Kong Investor Services Limited, in Hong Kong. Title to the H Shares will be effective starting from 8:00 a.m. on Tuesday, November 24, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination" in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the time mentioned above do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, November 24, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, November 24, 2026 (Hong Kong time). The H Shares will be traded in board lots of 50 H Shares each, and the stock code of the H Shares will be 9941.

Applicants who applied through the HKSCC EIPO channel will have their allotted Hong Kong Offer Shares registered in the name of HKSCC Nominees and deposited directly into CCASS for credit to their designated HKSCC Participant's stock account, and no action is required. Applicants who applied through the White Form eIPO service will have their allotted Hong Kong Offer Shares registered in their own names. If such applicants have a USI Facility held with the ASR, they can view and transfer their H Shares via the ASR's UNSRT system. If they do not have a USI Facility held with the ASR, they will become provisional system-members to receive the H Shares but will not be able to transfer title to, or otherwise manage, their H Shares (including submitting certain corporate action instructions) via the ASR's UNSRT system until they set up a USI Facility, and are recommended to contact the ASR directly at +852 2862 8555 to do so. For further details, please refer to the sections headed "How to Apply for Hong Kong Offer Shares – D. Credit of Allotted Shares and Refund of Application Monies" and "Important Information about our Company under USM Regime" in the Prospectus, the Company's website at www.sinotau.com and the Company's website dedicated to USM matters at https://ir.sinotau.com/en/investor-relations/uncertificated-securities-market/.

By order of the Board
Beijing Sinotau International Pharmaceutical Technology Co., Ltd.
Mr. Xu Xinsheng
Chairperson of the Board and Executive Director

Hong Kong, November 23, 2026

As at the date of this announcement, the Board comprises: (i) Mr. XU Xinsheng, Ms. TANG Yanmin, Mr. WANG Peng, Mr. CHU Wei and Mr. YU Wenbin as executive Directors; (ii) Mr. CHEN Daojin, Dr. ZHANG Yingjie, Dr. YE Suofu, Dr. HUANG Xu and Mr. HAO Bonan as non-executive Directors; and (iii) Ms. NI Hong, Dr. Jimmy Zhimin ZHANG, Mr. WU Haidong, Dr. YANG Yue and Dr. KANG Cailian as independent non-executive Directors.